GlassScriptPhysician profile
Devorah R Shagalov
NPI 1336584960
$2,603.70
in general payments reported to CMS, 2019-2025
24 companies · $755 in 2025
The $755 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $89.63 · 2021: $205 · 2022: $45.76 · 2023: $212 · 2024: $811 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $835.76 | 2019-2025 | |
| Genzyme Corporation | $291.09 | 2019-2024 | |
| Pfizer INC. | $172.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $152.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $152.44 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $135.55 | 2024 | Vtama |
| Allergan, INC. | $97.33 | 2019 | |
| Incyte Corporation | $85.08 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $81.40 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $75.83 | 2020-2025 | Ebglyss |
| Dermira, INC. | $72.03 | 2019-2021 | |
| Kerecis Limited | $61.13 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Almirall LLC | $59.64 | 2020-2025 | Klisyri |
| Biofrontera INC. | $54.61 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $52.14 | 2025 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $34.14 | 2019 | |
| Strata Skin Sciences, INC. | $30.53 | 2024 | Xtrac |
| Mayne Pharma Commercial LLC | $30.39 | 2025 | |
| Merz North America, INC. | $28.33 | 2024 | |
| Arcutis Biotherapeutics, INC. | $23.59 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $21.36 | 2025 | Ycanth |
| Epi Health, LLC | $20.43 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.18 | 2022 | |
| Janssen Biotech, INC. | $15.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devorah Shagalov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.